On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to have supported this clinical trial.
The trial demonstrated that ATYR1923 was safe and well-tolerated, 33% of patients were were able to taper off steroids completely, and there were observed improvements in forced vital capacity (FVC), cough and fatigue.
As next steps, aTyr Pharma plans to meet with the U.S. Food and Drug Administration to present the data and plans for subsequent clinical development and path to registration for ATYR1923 for pulmonary sarcoidosis. They expect to initiate a registrational trial in 2022.
FSR would like to thank all those with pulmonary sarcoidosis who participated in this trial and helped produce this exciting development. Your participation helps bring us closer to new, innovative treatments for sarcoidosis.
Read the full press release here.